Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes

Pediatric Diabetes

Volumn 9, Issue 3 PART 2, 2008, Pages 83-90

  Päivärinta, Minna ^a   Tapanainen, Päivi ^a   Veijola, Riitta ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Adolescents; Children; HbA1c; Insulin glargine; Ttype 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; OPTIPEN PRO 1;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; BODY HEIGHT; CHILD; CHILD CARE; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MORNING DOSAGE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RETROSPECTIVE STUDY; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; AGE OF ONSET; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY HEIGHT; BODY WEIGHT; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 44649109669     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00341.x     Document Type: Article

References (28)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177-188.
3. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001: 139: 804-812.
4. Mortensen HB, Robertson KJ, Aanstoot HJ et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998: 15: 752-759.
5. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986: 315: 215-219.
6. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999: 42: 1151-1167.
7. Bolli GB, Owens DR. Insulin glargine. Lancet 2000: 356: 443-445.
8. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000: 49: 2142-2148.
9. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003: 289: 2254-2264.
10. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. The pediatric study group of insulin glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 5: 369-376.
11. Colino E, López-CapapéM, Golmayo L, Álvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus ®) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005: 70: 1-7.
12. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (Lantus ®) on glycemic control in toddlers, children and adolescents with diabetes. Diabetes Technol Ther 2003: 5: 801-806.
13. Tamborlane WV, Kollman CS, Ruedy MW et al. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: Results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes 2005: 6: 13-16.
14. Sorva R, Perheentupa J, Tolppanen EM. A novel format for a growth chart. Acta Paediatr Scand 1984: 73: 527-529.
15. International Society for Pediatric and Adolescent Diabetes. In: Swift PGF, ed. International Diabetes Federation: ISPAD Consensus Guidelines for the Management of Type 1 Diabetes Mellitus in Children and Adolescents. Zeist, Amsterdam, The Netherlands: Publ. Medforum, 2000: 77-83.
16. Bradley C. The Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes, 2nd edn. Amsterdam, The Netherlands: Harwood Academic Publishers, 1996: 111-132.
17. Dunger DB, Edge JA, Skvor J. Insulin glargine provides long-term effective glycemic control in children and adolescents with type 1 diabetes. Diabetes 2002: 51 (Suppl. 2): A426.
18. Murphy NP, Keane SM, Ong KK et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003: 26: 799-804.
19. Chase HP, Dixon B, Pearson J et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003: 143: 737-740.
20. Jackson A, Ternand C, Brunzell C et al. Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes. Pediatr Diabetes 2003: 4: 64-69.
21. Salzano G, Lombardo F, Pustorino E, Foti M, Manzo V, De Luca F. Efficacy of insulin glargine in adolescents with type 1 diabetes. Pediatr Diabetes 2006: 7 (Suppl. 5): 33.
22. Thorisdottir RL, Bjarnason R, Konradsdottir E, Thorsson AV. Improved glycemic control after introduction of insulin glargine in children and adolescents. Pediatr Diabetes 2006: 7 (Suppl. 5): 33.
23. Alemzadeh R, Ellis JN, Holzum MK, Parton EA, Wyatt DT. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 2004: 114: 91-95.
24. Tan CY, Wilson DM, Buckingham B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004: 5: 80-86.
25. Raskin P, Klaff L, Bergenstal R, HalléJP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000: 23: 1666-1671.
26. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004: 8: 1-171.
27. Wang F, Carabino J, Cunegundo M. Insulin glargine: A systematic review of a long-acting insulin analogue. Clin Ther 2003: 25: 1541-1577.
28. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001: 18: 619-625.